← Back to patent-cliff list
Afamelanotide
Tier C — Watch / tradeAfamelanotide
The University Of Arizona
Originator
2014
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MCRs
Brand：PRENUMBRA, Scenesse
Indications (approved)：Erythropoietic protoporphyria
Regional status
US
Approved
2019-10-08
EU
Approved
2014-12-22
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Afamelanotide?
Approved indications include: Erythropoietic protoporphyria.
When does the Afamelanotide patent expire?
No public expiry year is available for Afamelanotide yet; this page updates once verified.
How do I get a quote for Afamelanotide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29